Healthcare
ORIC Pharmaceuticals, Inc.(ORIC)
Live Price
Offline$8.49
-1.62% today
1Y Change
-12.90%
Window
Jun 25, 2025 โ Jun 23, 2026
- Market Cap
- $980.00M
- Revenue Growth
- 0.0%
- EPS Growth
- +19.7%
- Dividend Yield
- 0.0%
Coverage: 249 bars ยท Jun 25, 2025 โ Jun 23, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
ORIC Pharmaceuticals, Inc. (ORIC) is a Healthcare stock with a market cap of $980.00M and listed on NASDAQ. The stock last traded around $8.49 and down 12.9% across the available one-year price window (Jun 25, 2025 โ Jun 23, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +19.7%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +19.7%, free cash flow -0.2% with operating margin 0.0% and ROIC -36.3%. Stock Foundry combines ORIC price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
0.0% vs +7.6% peer median
Operating Margin
Below sector median
0.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 4, 2026, but the surprise data is still limited.
The setup is mixed rather than one-directional
Revenue is 0.0% and EPS is +19.7%, while operating margin sits near 0.0%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +2.0% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 4, 2026 | โ | -0.6% | -6.6% | -20.9% |
2026 Feb 23, 2026 | +11.8% | +14.6% | +18.5% | -5.0% |
2025 Nov 13, 2025 | +19.5% | +0.5% | -5.8% | -23.1% |
Benchmark Edge
ORIC vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
ORIC
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
ORIC Max Drawdown
-48.13%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for ORIC and SPY.
Company Overview
ORIC Pharmaceuticals, Inc.
NASDAQ Global Select
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer; and ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms. It has a license and collaboration agreement with Voronoi Inc.; and a license agreement with Mirati Therapeutics, Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.
- Leadership
- Jacob Chacko
- IPO Date
- Apr 24, 2020
- Employees
- 122
- Street Address
- 240 East Grand Avenue
- Mailing
- South San Francisco, CA, 94080
- Region
- South San Francisco, CA, US
- Reporting Currency
- USD
- Investor Line
- 650 388 5600
- Last Updated
- May 3, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- โ
- Price/Book
- 2.2
Growth
- Revenue
- 0.0%
- EPS
- +19.7%
- Free Cash Flow
- -0.2%
Profitability
- Gross Margin
- 0.0%
- Operating Margin
- 0.0%
- Net Margin
- 0.0%
- ROE
- -38.8%
- ROIC
- -36.3%
Balance Sheet
- Debt/Equity
- 0.03
- Current Ratio
- 14.13
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.